Sensyne Health Plc collaborates with Bristol Myers Squibb

Be the First to Comment Read

Sensyne Health Plc collaborates with Bristol Myers Squibb

Sensyne Health Plc (LON: SENS) has entered a research collaboration agreement with Bristol Myers Squibb.

  • The collaboration for which no financial terms have been disclosed will focus on applying company’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with varied diseases within the broader group of MPNs (Myeloproliferative Neoplasms).
  • It is the UK Clinical AI company’s fourth successive partnership with a major pharmaceutical company after Alexion, Roche and Bayer.
  • On 23 October 2020, the stocks of the company were up by 6.49% from the previous closing, hovering at around GBX 98.50 at 09:27 AM GMT+1.

Disclaimer

Speak your Mind